桂龙咳喘宁品牌怎么样 申请店铺

我要投票 桂龙咳喘宁在医疗器械行业中的票数:654 更新时间:2026-01-05
桂龙咳喘宁是哪个国家的品牌?「桂龙咳喘宁」是桂龙药业(安徽)有限公司旗下著名品牌。该品牌发源于安徽省马鞍山市,由创始人Stephen John Coplin在2003-11-25期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力桂龙咳喘宁品牌出海!将品牌入驻外推网,定制桂龙咳喘宁品牌推广信息,可以显著提高桂龙咳喘宁产品曝光,简直是跨境电商爆单神器!目前仅需1000元/年哦~

桂龙咳喘宁怎么样

桂龙咳喘宁,知名咳嗽药品牌,成立于1989年,高新技术企业,中药呼吸系统和咽喉品类领域领先企业,集研发/生产/销售于一体的中药企业


桂龙药业成立于1989年,是集研发、生产、销售为一体的中药行业企业。桂龙,取自谐音“贵”“隆”,意为富贵华荣兴旺发达。且“桂”,有桂树四季翠绿,香飘万里而古朴典雅,是传统中药的化身;“龙”,象征着东方文化与蓄势勃发的力量。

公司拥有员工约1000人,总部位于福建省厦门市,在安徽省马鞍山市和山西省忻州市设有两个生产基地,总占地面积11万平方米,建筑面积近4万平方米,均为现代化的花园式GMP工厂。 桂龙药业在全国设立27个销售办事处,拥有500人的销售团队,销售人员有效管理近6万家零售终端门店,产品覆盖全国近三十万家零售药店,以及全国所有主流连锁药店。

2003年经当涂县委、县人大招商引资在当涂经济开发区征地120亩,投资5000万元,建立了一座符合GMP要求的生产企业——桂龙药业(安徽)有限公司。公司目前拥有国药准字号品种31个,主要生产经营范围为:片剂、胶囊剂、颗粒剂、煎膏剂、及生产加工、经营糖果。其主导产品主要有:慢严舒柠牌清喉利咽颗粒、桂龙咳喘宁胶囊、新生化颗粒、复方柴胡安神颗粒、好爽糖等。科技创新、管理创新、岗位创新、市场创新是企业发展的原动力。科技人员占员工比例36%以上。公司拥有的技术研发中心和检测中心,保障了公司科技的可持续发展,保障了药品的质量和药品的安全。

桂龙专注于中药呼吸系统和咽喉品类领域,创立了国内呼吸系统和咽喉领域两个品牌“桂龙”牌、“慢严舒柠”牌。

“有健康就有桂龙,桂龙药业、健康事业”是桂龙药业的宗旨;品牌战略、人才战略、创新战略是桂龙发展的三个支撑;“敬业”、“诚信”、“责任”、“创新”是桂龙发展的核心理念。随着企业的发展壮大,桂龙药业现有的生产与研发平台不足以支撑桂龙药业未来若干年的迅速持续发展,为此桂龙药业决定在当涂经开区征地数百亩,以国内专业的制药技术和工艺装备,打造一个集生物医药生产和研究开发于一体的现代化医药产业园,以此支撑桂龙未来十多年的长足发展和技术创新、科技进步。


Guilong Kechuanning, a famous cough medicine brand, was founded in 1989. It is a high-tech enterprise, a leading enterprise in the field of traditional Chinese medicine respiratory system and throat category. Guilong pharmaceutical, a traditional Chinese medicine enterprise integrating R & D, production and sales, was founded in 1989. It is a traditional Chinese Medicine enterprise integrating R & D, production and sales. Guilong, from the homonym "Gui" and "long", means prosperity and prosperity. And "Gui" is the embodiment of traditional Chinese medicine, which has four seasons of green, fragrant and elegant, and "long" symbolizes the power of Oriental culture and vigorous development. The company has about 1000 employees and its headquarter is located in Xiamen City, Fujian Province. It has two production bases in Maanshan City, Anhui Province and Xinzhou City, Shanxi Province, covering a total area of 110000 square meters and a building area of nearly 40000 square meters, all of which are modern garden GMP factories. Guilong pharmaceutical has 27 sales offices in China, with a sales team of 500 people. The sales staff effectively manage nearly 60000 retail terminal stores, covering nearly 300000 retail pharmacies and all mainstream chain pharmacies in China. In 2003, Dangtu County Party committee and County People's Congress invested 120 mu of land in Dangtu economic development zone and invested 50 million yuan to establish a GMP compliant production enterprise - Guilong Pharmaceutical (Anhui) Co., Ltd. At present, the company has 31 varieties of State Pharmaceutical quasi brand, the main production and business scope are: tablets, capsules, granules, decoctions, as well as the production, processing and operation of candy. Its main products are: Manyan shuning brand Qinghou Liyan granules, Guilong Kechuanning capsule, xinbiochemical granules, compound Bupleurum Anshen granules, haoshuangtang, etc. Technological innovation, management innovation, post innovation and market innovation are the driving force of enterprise development. Science and technology personnel account for more than 36% of employees. The technology R & D center and testing center of the company ensure the sustainable development of the company's science and technology and the quality and safety of drugs. Focusing on the field of respiratory system and throat category of traditional Chinese medicine, Guilong has established two domestic brands in the field of respiratory system and throat, "Guilong" brand and "slow, strict, shuning" brand. The aim of Guilong pharmaceutical industry is to "have health, Guilong pharmaceutical industry and health cause"; brand strategy, talent strategy and innovation strategy are the three supports for the development of Guilong; dedication, integrity, responsibility and innovation are the core concepts for the development of Guilong. With the development of enterprises, the existing production and R & D platform of Guilong pharmaceutical industry is not enough to support the rapid and sustainable development of Guilong pharmaceutical industry in the next few years. Therefore, Guilong pharmaceutical industry decided to take hundreds of mu of land in Dangtu Economic Development Zone to build a modern pharmaceutical industrial park integrating biological pharmaceutical production and research and development with domestic professional pharmaceutical technology and process equipment, so as to support Guilong pharmaceutical industry Long's considerable development and technological innovation and scientific and technological progress in the next ten years.

本文链接: https://brand.waitui.com/0d765d197.html 联系电话:请联系客服添加 联系邮箱:请联系客服添加

外推网广告位招租,每天只要9块9

7×24h 快讯

快手盘中拉升,现涨超11%

36氪获悉,快手盘中拉升,现涨超11%。

2小时前

“尧乐科技”完成近亿元Pre-A轮融资

36氪获悉,“尧乐科技”已完成近亿元Pre-A轮融资,云道资本担任长期独家财务顾问。科沃斯参股的隐峰揽秀基金领投,硅港资本、初辉资本跟投。本轮资金将重点投向核心技术迭代、出海市场扩展以及硬件规模化量产。

2小时前

中国12月RatingDog服务业PMI 52

36氪获悉,中国12月RatingDog服务业PMI 52,前值52.1。

2小时前

中国银行间市场交易商协会:加大对债券交易记录相关违规行为惩戒力度

36氪获悉,中国银行间市场交易商协会发布公告,近一段时间以来,中国银行间市场交易商协会(以下简称交易商协会)在相关业务检查和自律调查过程中发现,部分机构内控缺失、合规风控流于形式,且一些机构未按要求保存债券交易记录的问题较为普遍,严重阻碍还原交易真相,不利于有效监管和打击违法违规。针对上述情形,交易商协会将加大对相关违规行为的惩戒力度。对存在以下问题的机构将从严从重处理,根据具体违规行为的情节轻重给予相应自律处分,具体包括:一、未按规定建立健全债券交易记录保存相关内控制度;二、合规风控流于形式,未有效落实债券交易记录保存相关内控制度;三、债券交易记录未按规定全程留痕;四、对涉嫌严重违法违规的交易,无法提供完整交易记录还原交易真相;五、其他违反债券交易记录保存相关要求的行为。

2小时前

两部门:选择一批绿色发展基础较好的公路项目,开展政府采购支持公路绿色低碳发展试点

36氪获悉,财政部、交通运输部发布关于组织开展“政府采购支持公路绿色低碳发展”试点工作的通知,试点任务为:选择一批绿色发展基础较好的公路项目,开展政府采购支持公路绿色低碳发展试点,积极推广应用“新材料、新技术、新工艺、新方法”(以下简称“四新”技术),探索应用绿色低碳技术、绿色材料(含设备,下同)的有效模式。试点目标为:到2028年,政府采购支持公路绿色低碳发展试点工作取得明显进展,在公路领域创新应用绿色低碳技术和绿色材料,基本形成支持公路绿色低碳发展的政府采购需求标准,政府采购支持公路绿色低碳发展的政策措施和工作机制更加完善,推动公路绿色低碳发展水平持续提升。

2小时前

本页详细列出关于桂龙咳喘宁的品牌信息,含品牌所属公司介绍,桂龙咳喘宁所处行业的品牌地位及优势。
咨询